Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Eclipse Regenesis logo — The First Tissue Regeneration Therapy For Short Bowel Syndro...

Eclipse Regenesis

The First Tissue Regeneration Therapy For Short Bowel Syndrome (SBS).

Founded 2017 United States Menlo Park, United States 7 employees Grant Health Care, Medical Devices

General Information

Company Name Eclipse Regenesis
Founded Year 2017
Location United States Menlo Park, United States +1
Employees 7
Industries Health Care, Medical Devices
Funding Stage Grant
Social

Get notified when Eclipse Regenesis moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Eclipse Regenesis

Eclipse Regenesis is a health care and medical device startup founded in 2017, headquartered in the United States. The company's slogan, "The First Tissue Regeneration Therapy For Short Bowel Syndrome (SBS)," encapsulates its groundbreaking mission. Eclipse Regenesis aims to combat the devastating condition of Short Bowel Syndrome, where the small intestine is too short to absorb sufficient nutrients, through their innovative Eclipse XL1 therapy. The Eclipse XL1 therapy is designed to address SBS by leveraging an entirely mechanical, repeatable approach to grow 2-3x longer, healthy intestine within 2-3 weeks. This approach represents a significant advancement in the medical field, offering hope to those affected by SBS. Studies have shown that the new tissue generated by the Eclipse XL1 therapy can absorb nutrients and function as well as, if not better than, healthy intestinal tissue. It’s important to note that the Eclipse XL1 device is currently an investigational product, restricted by Federal law to investigational use. As a result, it is not yet available for commercial sale in the U.S. or any other region. The company's commitment to innovation and its potentially impactful solution for SBS position Eclipse Regenesis as a compelling player in the healthcare and medical devices industries.

No funding data available for Eclipse Regenesis yet.

Get notified when Eclipse Regenesis raises funding

Eclipse Regenesis Alternatives & Competitors

Eclipse Regenesis vs
Therachon
Therachon Switzerland

Life-Transforming Therapies - Developing novel therapeutics for serious rare conditions

Series B
1 employees
Biotechnology, Health and Wellness
Eclipse Regenesis vs
Alpha Tau Medical
Alpha Tau Medical Israel

Revolutionary Alpha Emitters Radiotherapy

Post Ipo Equity
98 employees
Health Care, Medical Devices
Eclipse Regenesis vs
Xoft
Xoft United States

The Xoft® Electronic Brachytherapy System® is an isotope-free radiation treatment cleared by the FDA...

Debt Financing
52 employees
Manufacturing, Medical Devices

FAQ About Eclipse Regenesis

The First Tissue Regeneration Therapy For Short Bowel Syndrome (SBS).
Eclipse Regenesis was founded in 2017.
Eclipse Regenesis is headquartered in Menlo Park, United States.
Eclipse Regenesis operates in the following industries: Health Care, Medical Devices.
Eclipse Regenesis has approximately 7 employees.
Top alternatives and competitors to Eclipse Regenesis include Therachon, Alpha Tau Medical, Xoft, ClostraBio, Inc, Actinium Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Eclipse Regenesis and Therachon are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Eclipse Regenesis and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy